Comparison · NCT02495285-2160655a
Gelofusine 4% vs Gelaspan 4%: Number of Participants With (Serious) Adverse Events / Reactions
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Gelofusine 4% vs Gelaspan 4%: Number of Participants With (Serious) Adverse Events / Reactions. Trial comparisons, record NCT02495285-2160655a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02495285-2160655a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00826 | 0.00146 | 0.0453 | wilson | |
| Risk in group 2 | 0.00833 | 0.00325 | 0.0212 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0000689 | -0.0146 | 0.0373 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.992 | 0.112 | 8.79 | log | |
| Odds ratio, group 1 over group 2 | 0.992 | 0.11 | 8.95 | log | |
| Number needed to treat, for one fewer participant with the outcome on Gelofusine 4% than on Gelaspan 4% | 14,500 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Gelofusine 4% | Children age ≤ 12 years~Gelofusine 4% | 1 | 121 | OG000 |
| Group 2 | Gelaspan 4% | Children age ≤ 12 years~Gelaspan 4% | 4 | 480 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With (Serious) Adverse Events / Reactions
- Description
- Time frame
- Before (0 - 2 h) and up to 2 h after infusion of gelatin solutions
- Population
Source ClinicalTrials.gov
Trial
- Title
- Gelatines in Pediatric PatientS
- NCT number
- NCT02495285
- Phases
- Conditions
- Treatment of Hypovolemia and Shock
- Interventions
- Gelofusine 4%, Gelaspan 4%
- Lead sponsor
- B. Braun Melsungen AG
- Results first posted
- 2024-12-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02495285?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02495285-2160655a